Imatinib-resistant GIST: the decisions you may face
4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Progression on imatinib 400 mg
Confirm adherence and plasma level; dose escalation to 800 mg (especially exon 9); local therapy for isolated progression while continuing imatinib.
The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.
Thermal ablation kills a tumour with heat or cold delivered through a needle, with no incision required.
- Outpatient, repeatable
- Preserves organ function
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Take with a meal and a large glass of water.
- Size limit ~3 cm
- Heat-sink near vessels
- Between Imatinib and Thermal ablation (RFA, microwave, cryo), which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (progression on imatinib 400 mg), which of the standard options do you recommend and why?Why: Guideline options include: Confirm adherence and plasma level; dose escalation to 800 mg (especially exon 9); local therapy for isolated progression while continuing imatinib.
- Am I a candidate for Imatinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.
Second line
Sunitinib; ripretinib as an alternative, preferred where the secondary mutation is in exon 17 or 18 (INTRIGUE subgroup; INSIGHT ongoing).
Sunitinib is an anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.
A fourth-line GIST drug that locks KIT in an off state regardless of which resistance mutation the tumour has acquired.
A blood test that reads fragments of DNA shed by the tumour, so you can genotype or monitor cancer without a needle in the tumour.
- Minimally invasive, repeatable
- Whole-body clonal picture
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibPhase 3NCT03673501453 peopleevidence 48Tests Sunitinib, RipretinibA Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
No headline result recorded yet.
- Tests Ripretinib, Liquid biopsy (ctDNA)Second-line GIST with KIT exon 11 + exon 17/18 mutations (ctDNA-selected): ripretinib vs sunitinib
No headline result recorded yet.
- Avoid grapefruit.
- Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
- Low shedding in some tumours (brain, early-stage)
- Clonal haematopoiesis false positives
- Between Sunitinib, Ripretinib and Liquid biopsy (ctDNA), which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib and INSIGHT, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (second line), which of the standard options do you recommend and why?Why: Guideline options include: Sunitinib; ripretinib as an alternative, preferred where the secondary mutation is in exon 17 or 18 (INTRIGUE subgroup; INSIGHT ongoing).
- Am I a candidate for Sunitinib, Ripretinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib and INSIGHT apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Third line
Regorafenib (GRID).
A sorafenib successor that became the first second-line drug proven to prolong life in liver cancer (2017).
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Take with a low-fat breakfast (under 30% fat).
- Not recommended in severe impairment; hepatotoxicity is a boxed warning.
- Is Regorafenib the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?Why: A single standard does not mean a single choice; timing and trials are decisions too.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (third line), which of the standard options do you recommend and why?Why: Guideline options include: Regorafenib (GRID).
- Am I a candidate for Regorafenib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.
Fourth line and beyond
Ripretinib (INVICTUS); imatinib rechallenge; trials of next-generation KIT inhibitors.
A fourth-line GIST drug that locks KIT in an off state regardless of which resistance mutation the tumour has acquired.
The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.
IDRX-42 is an experimental small-molecule drug from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.
NB003 is an experimental small-molecule drug from Ningbo Newbay Technology Development in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.
Bezuclastinib is an experimental small-molecule drug from Cogent Biosciences in phase 3 trials for gastrointestinal stromal tumour, aimed at KIT and MET.
- Tests RipretinibAdvanced GIST after ≥3 kinase inhibitors: ripretinib vs placebo
PFS HR 0.15; OS HR 0.36.
Progression-free survival (median) (months): Ripretinib 6.3 (n=85) vs Placebo 1 (n=44) · HR 0.15 · source
- Take with a meal and a large glass of water.
- Between Ripretinib, Imatinib, IDRX-42 and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in INVICTUS, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (fourth line and beyond), which of the standard options do you recommend and why?Why: Guideline options include: Ripretinib (INVICTUS); imatinib rechallenge; trials of next-generation KIT inhibitors.
- Am I a candidate for Ripretinib, Imatinib, IDRX-42 or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of INVICTUS apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.